{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:50Z","timestamp":1793367350017,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-123732OB-I00"],"award-info":[{"award-number":["PID2021-123732OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-125118OB-I00"],"award-info":[{"award-number":["PID2021-125118OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-106579RB-I00"],"award-info":[{"award-number":["PID2019-106579RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-142617NB-I00"],"award-info":[{"award-number":["PID2022-142617NB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-141700OB-I00"],"award-info":[{"award-number":["PID2022-141700OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PRE2022-101764"],"award-info":[{"award-number":["PRE2022-101764"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["202013-30-31-32"],"award-info":[{"award-number":["202013-30-31-32"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"crossref","award":["2021-SGR-01358"],"award-info":[{"award-number":["2021-SGR-01358"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"crossref","award":["2021-SGR 0108"],"award-info":[{"award-number":["2021-SGR 0108"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003086","name":"Basque Government","doi-asserted-by":"crossref","award":["PI20\/00153"],"award-info":[{"award-number":["PI20\/00153"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eitb Maratoia","award":["BIO22\/ALZ\/010"],"award-info":[{"award-number":["BIO22\/ALZ\/010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Dysregulation of the endocannabinoid system (eCBS) and the loss of CB1 receptors (CB1R) in the basal ganglia are well-established hallmarks of Huntington\u2019s disease (HD). As a result, significant research efforts have focused on targeting the eCBS to alleviate motor disturbances associated with the disease. Beyond its role in motor control, the eCBS is a complex signaling network critically involved in regulating learning and memory. Despite this, the potential involvement of eCBS dysfunction in the cognitive decline characteristic of HD, often manifested well before motor dysfunction, has remained largely unexplored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>CB1R expression in the hippocampus was evaluated in both human HD samples and HD mouse models (R6\/1 and Hdh<jats:sup>Q7\/Q111<\/jats:sup> models, including both sexes) using Western blotting, immunohistochemistry, and radioligand binding assays. To restore CB1R function, CB1R agonist WIN-55212\u20132 was systemically administered, or viral vectors encoding CB1R were locally infused into the hippocampus of HD mice. A multidisciplinary approach combining behavioral, biochemical, electrophysiological, and morphological analyses, was employed to investigate the molecular mechanisms underlying the effects of CB1R activation in the context of HD-related cognitive dysfunction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In both human HD samples and HD mouse models, CB1R protein levels were reduced in the hippocampus, accompanied by structural synaptic alterations and impairment in spatial, recognition and working memory. Moreover, hippocampal depolarization-induced suppression of inhibition was significantly disrupted in R6\/1 mice. Administration of WIN-55212\u20132 successfully restored these synaptic and cognitive deficits. Immunohistochemical analysis revealed that the CB1R decrease was specifically localized to GABAergic interneurons within the hippocampus. Notably, targeted restoration of CB1R expression in these interneurons via viral vector delivery was sufficient to rescue hippocampal-dependent memory deficits in HD mice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study suggests that impaired CB1R function in hippocampal GABAergic interneurons contributes to memory dysfunction in HD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40035-025-00500-w","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T07:35:42Z","timestamp":1756107342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington\u2019s disease models"],"prefix":"10.1186","volume":"14","author":[{"given":"Nadia","family":"Di Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Bengoetxea de Tena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sanchez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Pereda-Velarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Enfedaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"G\u00f3nzalez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis Maria Miquel","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Analia","family":"Bortolozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rodriguez-Puertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Costas-Insua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Molina-Porcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vazquez-Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Ozaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrudis","family":"Perea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gin\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"500_CR1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.","journal-title":"Nat Rev Dis Primers"},{"key":"500_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"M MacDonald","year":"1993","unstructured":"MacDonald M. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"500_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington\u2019s disease: a clinical review. Eur J Neurol. 2018;25:24\u201334.","journal-title":"Eur J Neurol"},{"key":"500_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RLM. The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience. 2000;97:505\u201319.","journal-title":"Neuroscience"},{"key":"500_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","volume":"51","author":"K Van Laere","year":"2010","unstructured":"Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G, et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med. 2010;51:1413\u20137.","journal-title":"J Nucl Med"},{"issue":"Pt 1","key":"500_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/brain\/awq278","volume":"134","author":"C Bl\u00e1zquez","year":"2011","unstructured":"Bl\u00e1zquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease. Brain. 2011;134(Pt 1):119\u201336.","journal-title":"Brain"},{"key":"500_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","volume":"163","author":"MJ Dowie","year":"2009","unstructured":"Dowie MJ, Bradshaw HB, Howard ML, Nicholson LFB, Faull RLM, Hannan AJ, et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington\u2019s disease. Neuroscience. 2009;163:456\u201365.","journal-title":"Neuroscience"},{"key":"500_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/10298420290030514","volume":"4","author":"I Lastres-Becker","year":"2002","unstructured":"Lastres-Becker I, G\u00f3mez M, Miguel R, Ramos JA, Fern\u00e1ndez-Ruiz J. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington\u2019s disease. Neurotox Res. 2002;4:601\u20138.","journal-title":"Neurotox Res"},{"key":"500_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","volume":"929","author":"I Lastres-Becker","year":"2002","unstructured":"Lastres-Becker I, Berrendero F, Lucas JJ, Martin-Aparicio E, Yamamoto A, Ramos JA, et al. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington\u2019s disease. Brain Res. 2002;929:236\u201342.","journal-title":"Brain Res"},{"key":"500_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.pneurobio.2006.11.006","volume":"81","author":"M Maccarrone","year":"2007","unstructured":"Maccarrone M, Battista N, Centonze D. The endocannabinoid pathway in Huntington\u2019s disease: a comparison with other neurodegenerative diseases. Prog Neurobiol. 2007;81:349\u201379.","journal-title":"Prog Neurobiol"},{"key":"500_CR11","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2174\/138161208785740108","volume":"14","author":"M Pazos","year":"2008","unstructured":"Pazos M, Sagredo O, Fernandez-Ruiz J. The endocannabinoid system in Huntingtons disease. Curr Pharm Des. 2008;14:2317\u201325.","journal-title":"Curr Pharm Des"},{"key":"500_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.1471-4159.2003.01595.x","volume":"84","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, De Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fern\u00e1ndez-Ruiz J. Compounds acting at the endocannabinoid and\/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington\u2019s disease. J Neurochem. 2003;84:1097\u2013109.","journal-title":"J Neurochem"},{"key":"500_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3390\/ijms18040684","volume":"18","author":"S Valdeolivas","year":"2017","unstructured":"Valdeolivas S, Sagredo O, Delgado M, Pozo M, Fern\u00e1ndez-Ruiz J. Effects of a sativex-like combination of phytocannabinoids on disease progression in R6\/2 mice, an experimental model of Huntington\u2019s disease. Int J Mol Sci. 2017;18:684.","journal-title":"Int J Mol Sci"},{"key":"500_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s13311-015-0367-5","volume":"12","author":"S Arjmand","year":"2015","unstructured":"Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens GJ, Shabani M. Cannabinoids and tremor induced by motor-related disorders: friend or foe? Neurotherapeutics. 2015;12:778\u201387.","journal-title":"Neurotherapeutics"},{"key":"500_CR15","volume-title":"Endocannabinoid system as a new therapeutic avenue for the treatment of Huntington\u2019s disease from pathophysiology to treatment of Huntington\u2019s disease","author":"K Saramak","year":"2022","unstructured":"Saramak K, Szejko N. Endocannabinoid system as a new therapeutic avenue for the treatment of Huntington\u2019s disease from pathophysiology to treatment of Huntington\u2019s disease. London: IntechOpen; 2022."},{"key":"500_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/biom13091388","volume":"13","author":"V Voicu","year":"2023","unstructured":"Voicu V, Brehar F-M, Toader C, Covache-Busuioc R-A, Corlatescu AD, Bordeianu A, et al. Cannabinoids in medicine: a multifaceted exploration of types, therapeutic applications, and emerging opportunities in neurodegenerative diseases and cancer therapy. Biomolecules. 2023;13:1388.","journal-title":"Biomolecules"},{"key":"500_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.wnn.0000152205.79033.73","volume":"18","author":"LJ Beglinger","year":"2005","unstructured":"Beglinger LJ, Nopoulos PC, Jorge RE, Langbehn DR, Mikos AE, Moser DJ, et al. White matter volume and cognitive dysfunction in early Huntington\u2019s disease. Cogn Behav Neurol. 2005;18:102\u20137.","journal-title":"Cogn Behav Neurol"},{"key":"500_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","volume":"11","author":"JS Paulsen","year":"2011","unstructured":"Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11:474\u201383.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"500_CR19","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/jnnp-2013-305114","volume":"84","author":"JS Paulsen","year":"2013","unstructured":"Paulsen JS, Smith MM, Long JD. Cognitive decline in prodromal Huntington disease: implications for clinical trials. J Neurol Neurosurg Psychiatry. 2013;84:1233\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"500_CR20","doi-asserted-by":"publisher","first-page":"106823","DOI":"10.1016\/j.phrs.2023.106823","volume":"194","author":"G Birolini","year":"2023","unstructured":"Birolini G, Valenza M, Ottonelli I, Talpo F, Minoli L, Cappelleri A, et al. Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington\u2019s disease. Pharmacol Res. 2023;194:106823.","journal-title":"Pharmacol Res"},{"key":"500_CR21","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1038\/s41591-023-02566-3","volume":"29","author":"DK Wilton","year":"2023","unstructured":"Wilton DK, Mastro K, Heller MD, Gergits FW, Willing CR, Fahey JB, et al. Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington\u2019s disease. Nat Med. 2023;29:2866\u201384.","journal-title":"Nat Med"},{"key":"500_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00702-024-02744-8","volume":"131","author":"KA Jellinger","year":"2024","unstructured":"Jellinger KA. Mild cognitive impairment in Huntington\u2019s disease: challenges and outlooks. J Neural Transm. 2024;131:289\u2013304.","journal-title":"J Neural Transm"},{"key":"500_CR23","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1111\/ene.15918","volume":"30","author":"P Wibawa","year":"2023","unstructured":"Wibawa P, Walterfang M, Malpas CB, Glikmann-Johnston Y, Poudel G, Razi A, et al. Selective perforant-pathway atrophy in Huntington disease: <scp>MRI<\/scp> analysis of hippocampal subfields. Eur J Neurol. 2023;30:2650\u201360.","journal-title":"Eur J Neurol"},{"key":"500_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/hbm.22214","volume":"35","author":"L Younes","year":"2014","unstructured":"Younes L, Ratnanather JT, Brown T, Aylward E, Nopoulos P, Johnson H, et al. Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp. 2014;35:792\u2013809.","journal-title":"Hum Brain Mapp"},{"issue":"8","key":"500_CR25","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1007\/s12035-017-0828-4","volume":"55","author":"E Alvarez-Periel","year":"2018","unstructured":"Alvarez-Periel E, Puigdell\u00edvol M, Brito V, Plattner F, Bibb JA, Alberch J, et al. Cdk5 contributes to Huntington\u2019s disease learning and memory deficits via modulation of brain region-specific substrates. Mol Neurobiol. 2018;55(8):6250\u201368.","journal-title":"Mol Neurobiol"},{"issue":"10","key":"500_CR26","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1172\/JCI74809","volume":"124","author":"V Brito","year":"2014","unstructured":"Brito V, Giralt A, Enriquez-Barreto L, Puigdell\u00edvol M, Suelves N, Zamora-Moratalla A, et al. Neurotrophin receptor p75NTRmediates Huntington\u2019s disease-associated synaptic and memory dysfunction. J Clin Invest. 2014;124(10):4411\u201328.","journal-title":"J Clin Invest"},{"key":"500_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41392-023-01547-9","volume":"8","author":"W Chen","year":"2023","unstructured":"Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther. 2023;8:333.","journal-title":"Signal Transduct Target Ther"},{"key":"500_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.neuroscience.2019.02.007","volume":"404","author":"Z Dargaei","year":"2019","unstructured":"Dargaei Z, Liang X, Serranilla M, Santos J, Woodin MA. Alterations in hippocampal inhibitory synaptic transmission in the R6\/2 mouse model of Huntington\u2019s disease. Neuroscience. 2019;404:130\u201340.","journal-title":"Neuroscience"},{"key":"500_CR29","doi-asserted-by":"publisher","first-page":"106225","DOI":"10.1016\/j.nbd.2023.106225","volume":"184","author":"M Espina","year":"2023","unstructured":"Espina M, Di Franco N, Bra\u00f1as-Navarro M, Navarro IR, Brito V, Lopez-Molina L, et al. The GRP78-PERK axis contributes to memory and synaptic impairments in Huntington\u2019s disease R6\/1 mice. Neurobiol Dis. 2023;184:106225.","journal-title":"Neurobiol Dis"},{"key":"500_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3233\/JHD-120023","volume":"1","author":"A Giralt","year":"2012","unstructured":"Giralt A, Saavedra A, Alberch J, P\u00e9rez-Navarro E. Cognitive dysfunction in Huntington\u2019s disease: humans, mouse models and molecular mechanisms. J Huntingtons Dis. 2012;1:155\u201373.","journal-title":"J Huntingtons Dis"},{"issue":"17","key":"500_CR31","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","volume":"24","author":"A Miguez","year":"2015","unstructured":"Miguez A, Barriga GG-D, Brito V, Straccia M, Giralt A, Gin\u00e9s S, et al. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington\u2019s disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum Mol Genet. 2015;24(17):4958\u201370.","journal-title":"Hum Mol Genet"},{"key":"500_CR32","doi-asserted-by":"publisher","first-page":"105024","DOI":"10.1016\/j.nbd.2020.105024","volume":"144","author":"S Rolfes","year":"2020","unstructured":"Rolfes S, Munro DAD, Lyras E-M, Matute E, Ouk K, Harms C, et al. Lentiviral delivery of human erythropoietin attenuates hippocampal atrophy and improves cognition in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol Dis. 2020;144:105024.","journal-title":"Neurobiol Dis"},{"key":"500_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/09540260902782760","volume":"21","author":"CS Breivogel","year":"2009","unstructured":"Breivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry. 2009;21:113\u201321.","journal-title":"Int Rev Psychiatry"},{"key":"500_CR34","doi-asserted-by":"publisher","first-page":"8332","DOI":"10.1007\/s12035-016-0313-5","volume":"54","author":"M Kruk-Slomka","year":"2017","unstructured":"Kruk-Slomka M, Dzik A, Budzynska B, Biala G. Endocannabinoid system: the direct and indirect involvement in the memory and learning processes\u2014a short review. Mol Neurobiol. 2017;54:8332\u201347.","journal-title":"Mol Neurobiol"},{"key":"500_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.lfs.2012.08.023","volume":"92","author":"MF Lazenka","year":"2013","unstructured":"Lazenka MF, Selley DE, Sim-Selley LJ. Brain regional differences in CB1 receptor adaptation and regulation of transcription. Life Sci. 2013;92:446\u201352.","journal-title":"Life Sci"},{"key":"500_CR36","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","volume":"11","author":"G Marsicano","year":"1999","unstructured":"Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci. 1999;11:4213\u201325.","journal-title":"Eur J Neurosci"},{"key":"500_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nlm.2008.01.009","volume":"90","author":"AL De Oliveira","year":"2008","unstructured":"De Oliveira AL, Genro BP, Diehl F, Quillfeldt JA. Differential role of the hippocampal endocannabinoid system in the memory consolidation and retrieval mechanisms. Neurobiol Learn Mem. 2008;90:1\u20139.","journal-title":"Neurobiol Learn Mem"},{"key":"500_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature00839","volume":"418","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530\u20134.","journal-title":"Nature"},{"key":"500_CR39","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1523\/JNEUROSCI.4718-10.2011","volume":"31","author":"H Tan","year":"2011","unstructured":"Tan H, Lauzon NM, Bishop SF, Chi N, Bechard M, Laviolette SR. Cannabinoid transmission in the basolateral amygdala modulates fear memory formation via functional inputs to the prelimbic cortex. J Neurosci. 2011;31:5300\u201312.","journal-title":"J Neurosci"},{"issue":"3","key":"500_CR40","doi-asserted-by":"publisher","first-page":"e12942","DOI":"10.1111\/bpa.12942","volume":"31","author":"S Borrego-\u00c9cija","year":"2021","unstructured":"Borrego-\u00c9cija S, Turon-Sans J, Ximelis T, Aldecoa I, Molina-Porcel L, Povedano M, et al. Cognitive decline in amyotrophic lateral sclerosis: neuropathological substrate and genetic determinants. Brain Pathol. 2021;31(3):e12942.","journal-title":"Brain Pathol"},{"key":"500_CR41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493\u2013506.","journal-title":"Cell"},{"key":"500_CR42","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/hmg\/ddl125","volume":"15","author":"A Lloret","year":"2006","unstructured":"Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, et al. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington\u2019s disease knock-in mice. Hum Mol Genet. 2006;15:2015\u201324.","journal-title":"Hum Mol Genet"},{"key":"500_CR43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s12035-013-8556-x","volume":"49","author":"M Anglada-Huguet","year":"2014","unstructured":"Anglada-Huguet M, Xifr\u00f3 X, Giralt A, Zamora-Moratalla A, Mart\u00edn ED, Alberch J. Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6\/1 mouse model of Huntington\u2019s disease. Mol Neurobiol. 2014;49:784\u201395.","journal-title":"Mol Neurobiol"},{"key":"500_CR44","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1093\/brain\/awz230","volume":"142","author":"J Creus-Muncunill","year":"2019","unstructured":"Creus-Muncunill J, Badillos-Rodr\u00edguez R, Garcia-Forn M, Masana M, Garcia-D\u00edaz Barriga G, Guisado-Corcoll A, et al. Increased translation as a novel pathogenic mechanism in Huntington\u2019s disease. Brain. 2019;142:3158\u201375.","journal-title":"Brain"},{"issue":"16","key":"500_CR45","first-page":"3144","volume":"26","author":"G Garc\u00eda-D\u00edaz Barriga","year":"2017","unstructured":"Garc\u00eda-D\u00edaz Barriga G, Giralt A, Anglada-Huguet M, Gaja-Capdevila N, Orlandi JG, Soriano J, et al. 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington\u2019s disease mouse model through specific activation of the PLC\u03b31 pathway. Hum Mol Genet. 2017;26(16):3144\u201360.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"500_CR46","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/hmg\/ddr552","volume":"21","author":"A Giralt","year":"2012","unstructured":"Giralt A, Puigdell\u00edvol M, Carret\u00f3n O, Paoletti P, Valero J, Parra-damas A, et al. Long-term memory deficits in Huntington\u2019s disease are associated with reduced CBP histone acetylase activity. Hum Mol Genet. 2012;21(6):1203\u201316.","journal-title":"Hum Mol Genet"},{"issue":"25","key":"500_CR47","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1093\/hmg\/ddv426","volume":"24","author":"M Puigdell\u00edvol","year":"2015","unstructured":"Puigdell\u00edvol M, Cherubini M, Brito V, Giralt A, Suelves N, Ballesteros J, et al. A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington\u2019s disease. Hum Mol Genet. 2015;24(25):7265\u201385.","journal-title":"Hum Mol Genet"},{"key":"500_CR48","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","volume":"46","author":"S Kuemmerle","year":"1999","unstructured":"Kuemmerle S, Gutekunst C-A, Klein AM, Li X-J, Li S-H, Beal MF, et al. Huntingtin aggregates may not predict neuronal death in Huntington\u2019s disease. Ann Neurol. 1999;46:842\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"500_CR49","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s12035-018-1126-5","volume":"56","author":"N Suelves","year":"2019","unstructured":"Suelves N, Miguez A, L\u00f3pez-Benito S, Barriga GG-D, Giralt A, Alvarez-Periel E, et al. Early downregulation of p75NTRby genetic and pharmacological approaches delays the onset of motor deficits and striatal dysfunction in Huntington\u2019s disease mice. Mol Neurobiol. 2019;56(2):935\u201353.","journal-title":"Mol Neurobiol"},{"key":"500_CR50","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"500_CR51","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/sj.npp.1300225","volume":"28","author":"M Schneider","year":"2003","unstructured":"Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology. 2003;28:1760\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"500_CR52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/B978-0-12-381296-4.00015-4","volume":"485","author":"G Barreda-G\u00f3mez","year":"2010","unstructured":"Barreda-G\u00f3mez G, Teresa Giralt M, Rodr\u00edguez-Puertas R. Methods to measure G-protein-coupled receptor activity for the identification of inverse agonists. Methods Enzymol. 2010;485:261\u201373.","journal-title":"Methods Enzymol"},{"issue":"1","key":"500_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2967\/jnumed.118.210393","volume":"60","author":"J Ceccarini","year":"2019","unstructured":"Ceccarini J, Ahmad R, Van de Vliet L, Casteels C, Vandenbulcke M, Vandenberghe W, et al. Behavioral symptoms in premanifest Huntington disease correlate with reduced frontal CB 1 R levels. J Nucl Med. 2019;60(1):115\u201321.","journal-title":"J Nucl Med"},{"key":"500_CR54","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1111\/j.1432-1033.2004.04460.x","volume":"271","author":"EA McCaw","year":"2004","unstructured":"McCaw EA, Hu H, Gomez GT, Hebb ALO, Kelly MEM, Denovan-Wright EM. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington\u2019s disease transgenic mice. Eur J Biochem. 2004;271:4909\u201320.","journal-title":"Eur J Biochem"},{"key":"500_CR55","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0306-4522(97)00436-3","volume":"83","author":"K Tsou","year":"1998","unstructured":"Tsou K, Brown S, Sa\u00f1udo-Pe\u00f1a MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83:393\u2013411.","journal-title":"Neuroscience"},{"key":"500_CR56","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1212\/01.WNL.0000138434.68093.67","volume":"63","author":"C Fennema-Notestine","year":"2004","unstructured":"Fennema-Notestine C, Archibald SL, Jacobson MW, Corey-Bloom J, Paulsen JS, Peavy GM, et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology. 2004;63:989\u201395.","journal-title":"Neurology"},{"key":"500_CR57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/B978-0-12-381328-2.00016-X","volume":"98","author":"J Kim","year":"2011","unstructured":"Kim J, Bordiuk OL, Ferrante RJ. Experimental models of HD and reflection on therapeutic strategies. Int Rev Neurobiol. 2011;98:419\u201381.","journal-title":"Int Rev Neurobiol"},{"key":"500_CR58","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"J-P Vonsattel","year":"1985","unstructured":"Vonsattel J-P, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington\u02bcs disease. J Neuropathol Exp Neurol. 1985;44:559\u201377.","journal-title":"J Neuropathol Exp Neurol"},{"key":"500_CR59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.nbd.2018.08.024","volume":"120","author":"M Garc\u00eda-Forn","year":"2018","unstructured":"Garc\u00eda-Forn M, Mart\u00ednez-Torres S, Garc\u00eda-D\u00edaz Barriga G, Alberch J, Mil\u00e0 M, Azkona G, et al. Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington\u2019s disease. Neurobiol Dis. 2018;120:88\u201397.","journal-title":"Neurobiol Dis"},{"key":"500_CR60","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","volume":"132","author":"J Palazuelos","year":"2009","unstructured":"Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity. Brain. 2009;132:3152\u201364.","journal-title":"Brain"},{"key":"500_CR61","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/glia.20838","volume":"57","author":"O Sagredo","year":"2009","unstructured":"Sagredo O, Gonz\u00e1lez S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. Cannabinoid CB 2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington\u2019s disease. Glia. 2009;57:1154\u201367.","journal-title":"Glia"},{"key":"500_CR62","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.3390\/biomedicines10123000","volume":"10","author":"B Vuic","year":"2022","unstructured":"Vuic B, Milos T, Tudor L, Konjevod M, Nikolac Perkovic M, Jazvinscak Jembrek M, et al. Cannabinoid CB2 receptors in neurodegenerative proteinopathies: new insights and therapeutic potential. Biomedicines. 2022;10:3000.","journal-title":"Biomedicines"},{"key":"500_CR63","doi-asserted-by":"publisher","first-page":"114384","DOI":"10.1016\/j.expneurol.2023.114384","volume":"364","author":"A Figueiredo","year":"2023","unstructured":"Figueiredo A, Cheer JF. Endocannabinoid regulation of hippocampus-dependent memory. Exp Neurol. 2023;364:114384.","journal-title":"Exp Neurol"},{"key":"500_CR64","doi-asserted-by":"publisher","first-page":"108736","DOI":"10.1016\/j.neuropharm.2021.108736","volume":"197","author":"BL Winters","year":"2021","unstructured":"Winters BL, Vaughan CW. Mechanisms of endocannabinoid control of synaptic plasticity. Neuropharmacology. 2021;197:108736.","journal-title":"Neuropharmacology"},{"key":"500_CR65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1523\/JNEUROSCI.0244-14.2015","volume":"35","author":"RP Murmu","year":"2015","unstructured":"Murmu RP, Li W, Szepesi Z, Li J-Y. Altered sensory experience exacerbates stable dendritic spine and synapse loss in a mouse model of Huntington\u2019s disease. J Neurosci. 2015;35:287\u201398.","journal-title":"J Neurosci"},{"key":"500_CR66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nbd.2015.09.001","volume":"95","author":"M Anglada-Huguet","year":"2016","unstructured":"Anglada-Huguet M, Vidal-Sancho L, Giralt A, Garc\u00eda-D\u00edaz Barriga G, Xifr\u00f3 X, Alberch J. Prostaglandin E2 EP2 activation reduces memory decline in R6\/1 mouse model of Huntington\u2019s disease by the induction of BDNF-dependent synaptic plasticity. Neurobiol Dis. 2016;95:22\u201334.","journal-title":"Neurobiol Dis"},{"key":"500_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-0-387-74349-3_11","volume-title":"Cannabinoids and the brain","author":"GL Gerdeman","year":"2008","unstructured":"Gerdeman GL. Endocannabinoids at the synapse: retrograde signaling and presynaptic plasticity in the brain. In: Cannabinoids and the brain. Boston, MA: Springer; 2008. p. 203\u201336."},{"issue":"8","key":"500_CR68","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3389\/fphar.2017.00921","volume":"19","author":"A Silva-Cruz","year":"2017","unstructured":"Silva-Cruz A, Carlstr\u00f6m M, Ribeiro JA, Sebasti\u00e3o AM. Dual influence of endocannabinoids on long-term potentiation of synaptic transmission. Front Pharmacol. 2017;19(8):921.","journal-title":"Front Pharmacol"},{"key":"500_CR69","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1097\/00001756-200006260-00044","volume":"11","author":"D Braida","year":"2000","unstructured":"Braida D, Sala M. Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats. NeuroReport. 2000;11:2025\u20139.","journal-title":"NeuroReport"},{"key":"500_CR70","doi-asserted-by":"publisher","first-page":"106235","DOI":"10.1016\/j.nbd.2023.106235","volume":"184","author":"I Fern\u00e1ndez-Moncada","year":"2023","unstructured":"Fern\u00e1ndez-Moncada I, Eraso-Pichot A, Dalla Tor T, Fortunato-Marsol B, Marsicano G. An enquiry to the role of CB1 receptors in neurodegeneration. Neurobiol Dis. 2023;184:106235.","journal-title":"Neurobiol Dis"},{"key":"500_CR71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.brainresbull.2020.03.014","volume":"160","author":"K Kataoka","year":"2020","unstructured":"Kataoka K, Bilkei-Gorzo A, Nozaki C, Togo A, Nakamura K, Ohta K, et al. Age-dependent alteration in mitochondrial dynamics and autophagy in hippocampal neuron of cannabinoid CB1 receptor-deficient mice. Brain Res Bull. 2020;160:40\u20139.","journal-title":"Brain Res Bull"},{"key":"500_CR72","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1016\/j.neurobiolaging.2013.05.027","volume":"34","author":"C Stumm","year":"2013","unstructured":"Stumm C, Hiebel C, Hanstein R, Purrio M, Nagel H, Conrad A, et al. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer\u2019s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiol Aging. 2013;34:2574\u201384.","journal-title":"Neurobiol Aging"},{"key":"500_CR73","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fnagi.2012.00034","volume":"4","author":"O Albayram","year":"2012","unstructured":"Albayram O, Bilkei-Gorzo A, Zimmer A. Loss of CB1 receptors leads to differential age-related changes in reward-driven learning and memory. Front Aging Neurosci. 2012;4:34.","journal-title":"Front Aging Neurosci"},{"issue":"43","key":"500_CR74","doi-asserted-by":"publisher","first-page":"15670","DOI":"10.1073\/pnas.0504640102","volume":"102","author":"A Bilkei-Gorzo","year":"2005","unstructured":"Bilkei-Gorzo A, Racz I, Valverde O, Otto M, Michel K, Sarstre M, et al. Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc Natl Acad Sci USA. 2005;102(43):15670\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"500_CR75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ijms24010026","volume":"24","author":"M Palmisano","year":"2022","unstructured":"Palmisano M, Gargano A, Olabiyi BF, Lutz B, Bilkei-Gorzo A. Hippocampal deletion of CB1 receptor impairs social memory and leads to age-related changes in the hippocampus of adult mice. Int J Mol Sci. 2022;24:26.","journal-title":"Int J Mol Sci"},{"key":"500_CR76","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bcp.2018.08.007","volume":"157","author":"E Aso","year":"2018","unstructured":"Aso E, Andr\u00e9s-Benito P, Ferrer I. Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model. Biochem Pharmacol. 2018;157:210\u20136.","journal-title":"Biochem Pharmacol"},{"key":"500_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.03.033","volume":"151","author":"RB Laprairie","year":"2019","unstructured":"Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, et al. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington\u2019s disease in the R6\/2 mouse model. Neuropharmacology. 2019;151:1\u201312.","journal-title":"Neuropharmacology"},{"key":"500_CR78","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/bph.17381","volume":"182","author":"M Moreno-Rodr\u00edguez","year":"2025","unstructured":"Moreno-Rodr\u00edguez M, Mart\u00ednez-Gardeazabal J, Bengoetxea de Tena I, Llorente-Ovejero A, Lombardero L, Gonz\u00e1lez de San Rom\u00e1n E, et al. Cognitive improvement via cortical cannabinoid receptors and choline-containing lipids. Br J Pharmacol. 2025;182:1038\u201358.","journal-title":"Br J Pharmacol"},{"key":"500_CR79","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/brainsci13030525","volume":"13","author":"M-H Yu","year":"2023","unstructured":"Yu M-H, Yang Q, Zhang Y-P, Wang J-H, Zhang R-J-Z, Liu Z-G, et al. Cannabinoid receptor agonist WIN55, 212\u20132 attenuates injury in the hippocampus of rats after deep hypothermic circulatory arrest. Brain Sci. 2023;13:525.","journal-title":"Brain Sci"},{"key":"500_CR80","doi-asserted-by":"publisher","first-page":"1527313","DOI":"10.3389\/fmolb.2024.1527313","volume":"11","author":"H Cho","year":"2025","unstructured":"Cho H. The N17 domain of huntingtin as a multifaceted player in Huntington\u2019s disease. Front Mol Biosci. 2025;11:1527313.","journal-title":"Front Mol Biosci"},{"key":"500_CR81","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1021\/acschemneuro.0c00226","volume":"11","author":"CH Lo","year":"2020","unstructured":"Lo CH, Pandey NK, Lim CK-W, Ding Z, Tao M, Thomas DD, et al. Discovery of small molecule inhibitors of Huntingtin exon 1 aggregation by FRET-based high-throughput screening in living cells. ACS Chem Neurosci. 2020;11:2286\u201395.","journal-title":"ACS Chem Neurosci"},{"key":"500_CR82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1087057107299428","volume":"12","author":"M Coufal","year":"2007","unstructured":"Coufal M, Maxwell MM, Russel DE, Amore AM, Altmann SM, Hollingsworth ZR, et al. Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments. SLAS Discov. 2007;12:351\u201360.","journal-title":"SLAS Discov"},{"key":"500_CR83","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.nbd.2011.03.006","volume":"42","author":"S Mievis","year":"2011","unstructured":"Mievis S, Blum D, Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis. 2011;42:524\u20139.","journal-title":"Neurobiol Dis"},{"key":"500_CR84","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1471-4159.2007.05149.x","volume":"105","author":"E Aso","year":"2008","unstructured":"Aso E, Ozaita A, Valdiz\u00e1n EM, Ledent C, Pazos \u00c1, Maldonado R, et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB 1 knockout mice. J Neurochem. 2008;105:565\u201372.","journal-title":"J Neurochem"},{"key":"500_CR85","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1088208","volume":"302","author":"G Marsicano","year":"2003","unstructured":"Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84\u20138.","journal-title":"Science"},{"key":"500_CR86","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.tpj.6500466","volume":"8","author":"MA Steiner","year":"2008","unstructured":"Steiner MA, Wanisch K, Monory K, Marsicano G, Borroni E, B\u00e4chli H, et al. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogen J. 2008;8:196\u2013208.","journal-title":"Pharmacogen J"},{"key":"500_CR87","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nrn3486","volume":"14","author":"AJ Koleske","year":"2013","unstructured":"Koleske AJ. Molecular mechanisms of dendrite stability. Nat Rev Neurosci. 2013;14:536\u201350.","journal-title":"Nat Rev Neurosci"},{"issue":"319","key":"500_CR88","first-page":"1683","volume":"2008","author":"J Tanaka","year":"1979","unstructured":"Tanaka J, Horiike Y, Matsuzaki M, Miyazaki T, Ellis-Davies GCR, Kasai H. Protein synthesis and neurotrophin-dependent structural plasticity of single dendritic spines. Science. 1979;2008(319):1683\u20137.","journal-title":"Science"},{"key":"500_CR89","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41598-022-27146-2","volume":"13","author":"JA Komorowska-M\u00fcller","year":"2023","unstructured":"Komorowska-M\u00fcller JA, Gellner A-K, Ravichandran KA, Bilkei-Gorzo A, Zimmer A, Stein V. Chronic low-dose \u03949-tetrahydrocannabinol (THC) treatment stabilizes dendritic spines in 18-month-old mice. Sci Rep. 2023;13:1390.","journal-title":"Sci Rep"},{"key":"500_CR90","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.brainres.2005.12.089","volume":"1085","author":"P Tagliaferro","year":"2006","unstructured":"Tagliaferro P, Javier Ramos A, Onaivi ES, Evrard SG, Lujilde J, Brusco A. Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55212\u20132. Brain Res. 2006;1085:163\u201376.","journal-title":"Brain Res"},{"key":"500_CR91","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1098\/rstb.2011.0384","volume":"367","author":"E Puighermanal","year":"2012","unstructured":"Puighermanal E, Busquets-Garcia A, Maldonado R, Ozaita A. Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philos Trans R Soc B Biol Sci. 2012;367:3254\u201363.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"500_CR92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.bjp.0705726","volume":"142","author":"MA Diana","year":"2004","unstructured":"Diana MA, Marty A. Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol. 2004;142:9\u201319.","journal-title":"Br J Pharmacol"},{"key":"500_CR93","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.nbd.2011.12.017","volume":"45","author":"V Chiodi","year":"2012","unstructured":"Chiodi V, Uchigashima M, Beggiato S, Ferrante A, Armida M, Martire A, et al. Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington\u2019s disease. Neurobiol Dis. 2012;45:983\u201391.","journal-title":"Neurobiol Dis"},{"key":"500_CR94","doi-asserted-by":"publisher","first-page":"180165","DOI":"10.1098\/rsob.180165","volume":"8","author":"Y-T Hsu","year":"2018","unstructured":"Hsu Y-T, Chang Y-G, Chern Y. Insights into GABAAergic system alteration in Huntington\u2019s disease. Open Biol. 2018;8:180165.","journal-title":"Open Biol"},{"key":"500_CR95","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.psychres.2018.06.012","volume":"267","author":"D-P Wang","year":"2018","unstructured":"Wang D-P, Yin H, Kang K, Lin Q, Su S-H, Hai J. The potential protective effects of cannabinoid receptor agonist WIN55,212\u20132 on cognitive dysfunction is associated with the suppression of autophagy and inflammation in an experimental model of vascular dementia. Psychiatry Res. 2018;267:281\u20138.","journal-title":"Psychiatry Res"},{"key":"500_CR96","doi-asserted-by":"publisher","first-page":"963457","DOI":"10.3389\/fpsyt.2022.963457","volume":"13","author":"CM Eddy","year":"2022","unstructured":"Eddy CM, Rickards H. Social cognition and quality of life in Huntington\u2019s disease. Front Psychiatry. 2022;13:963457.","journal-title":"Front Psychiatry"},{"key":"500_CR97","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.parkreldis.2011.01.020","volume":"17","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Mitchell IJ, Beck SR, Cavanna AE, Rickards HE. Altered subjective fear responses in Huntington\u2019s disease. Parkinsonism Relat Disord. 2011;17:386\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"500_CR98","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.nbd.2011.04.009","volume":"43","author":"AG Walker","year":"2011","unstructured":"Walker AG, Ummel JR, Rebec GV. Reduced expression of conditioned fear in the R6\/2 mouse model of Huntington\u2019s disease is related to abnormal activity in prelimbic cortex. Neurobiol Dis. 2011;43:379\u201387.","journal-title":"Neurobiol Dis"},{"key":"500_CR99","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.cortex.2011.02.014","volume":"47","author":"L Robotham","year":"2011","unstructured":"Robotham L, Sauter DA, Bachoud-L\u00e9vi A-C, Trinkler I. The impairment of emotion recognition in Huntington\u2019s disease extends to positive emotions. Cortex. 2011;47:880\u20134.","journal-title":"Cortex"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00500-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-025-00500-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00500-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:05:36Z","timestamp":1758740736000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-025-00500-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["500"],"URL":"https:\/\/doi.org\/10.1186\/s40035-025-00500-w","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The second author's name in citation details has been updated","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experimental procedures with mice were approved by the Local Ethical Committee of the University of Barcelona (CEEA 369\/19 and 439\/22) and the Generalitat de Catalunya (DAAM 369\/19), following European (86\/609\/EU) and Spanish (RD 1201\/2005) regulations for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}